

1 **Full title:**

2 ePOCT+ and the medAL-suite: Development of an electronic clinical decision support algorithm and
3 digital platform for pediatric outpatients in low- and middle-income countries

4 **Short title:**

5 Development of ePOCT+ and the medAL-suite

6 **Authors:**

7 Rainer Tan,^{1,2,3} Ludovico Cobuccio,^{1,2} Fenella Beynon,² Gillian Levine,² Nina Vaezipour,² Lameck
8 Luwanda,³ Chacha Mangu,⁴ Alan Vonlanthen,⁵ Olga De Santis,^{1,6} Nahya Salim,^{3,7} Karim Manji,⁷ Helga
9 Naburi,⁷ Lulu Chirande,⁷ Lena Matata,^{2,3} Method Bulongeleje,⁹ Robert Moshiro,⁷ Andolo Miheso,⁹
10 Peter Arimi,¹⁰ Ousmane Ndiaye,¹¹ Moctar Faye,¹¹ Aliou Thiongane,¹¹ Shally Awasthi,¹² Kovid
11 Sharma,¹³ Gaurav Kumar,² Josephine Van De Maat,¹⁴ Alexandra Kulinkina,^{2,15} Victor Rwandarwacu,²
12 Théophile Dusengumuremyi,² John Baptist Nkuranga,¹⁶ Emmanuel Rusingiza,^{17,18} Lisine Tuyisenge,¹⁷
13 Mary-Anne Hartley,¹⁹ Vincent Faivre,⁵ Julien Thabard,⁵ Kristina Keitel^{*2,20} & Valérie D’Acremont^{*1,2}

14 *Contributed equally

15 **Affiliations:**

- 16 1. Digital and Global Health Unit, Unisanté, Centre for Primary Care and Public Health, University of
17 Lausanne, Lausanne, Switzerland
- 18 2. Swiss Tropical and Public Health Institute, Basel, Switzerland
- 19 3. Ifakara Health Institute, Dar es Salaam, United Republic of Tanzania
- 20 4. National Institute of Medical Research – Mbeya Medical Research Centre, Mbeya, United
21 Republic of Tanzania
- 22 5. Department of Information and Technology, Unisanté, Center for Primary Care and Public Health,
23 University of Lausanne, Switzerland
- 24 6. Institute of Global Health, University of Geneva, Geneva, Switzerland
- 25 7. Department of Pediatrics and Child Health, Muhimbili University Health and Allied Sciences
26 (MUHAS), Dar es Salaam, United Republic of Tanzania

27 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 28 9. PATH, Nairobi, Kenya
- 29 10. College of Health Sciences, University of Nairobi, Nairobi, Kenya
- 30 11. Department of Pediatrics, Cheikh Anta Diop University, Dakar, Senegal
- 31 12. Department of Pediatrics, King George's Medical University, Lucknow, India
- 32 13. PATH, Lucknow, India
- 33 14. Radboudumc, Department of Internal Medicine and Radboudumc Center for Infectious Diseases,
34 Nijmegen, Netherlands
- 35 15. University of Basel, Basel, Switzerland
- 36 16. Department of Paediatrics, King Faisal Hospital, Kigali, Rwanda
- 37 17. University Teaching Hospital of Kigali, Kigali, Rwanda
- 38 18. School of Medicine and Pharmacy, University of Rwanda, Kigali, Rwanda
- 39 19. Intelligent Global Health, Machine Learning and Optimization Laboratory, Swiss Federal Institute
40 of Technology (EPFL), Lausanne, Switzerland
- 41 20. Paediatric Emergency Department, Department of Pediatrics, University Hospital Berne, Berne,
42 Switzerland

43

44 **Corresponding author:**

45 Dr. Rainer Tan

46 Digital & Global Health Unit

47 Unisanté, Centre for Primary Care and Public Health, University of Lausanne

48 Lausanne, Switzerland

49 Email: rainer.tan@unisante.ch

50 Tel: +255 676 020 505

51 **Keywords:** Clinical decision support algorithm, mHealth, digital health, child health, global health,

52 fever, antibiotic stewardship, quality of care

53

54

55 **ABSTRACT:**

56 Electronic clinical decision support algorithms (CDSAs) have been developed to address high
57 childhood mortality and inappropriate antibiotic prescription by helping clinicians adhere to guidelines.
58 Previously identified challenges of CDSAs include its limited scope, usability, and outdated clinical
59 algorithms. To address these challenges we developed ePOCT+, a CDSA for the care of pediatric
60 outpatients in low- and middle-income settings, and the medical algorithm suite (medAL-suite), a
61 software for the creation and execution of CDSAs. Following the principles of digital development, we
62 aim to describe the process and lessons learnt from the development of ePOCT+ and the medAL-
63 suite.

64 In particular, this work outlines the systematic integrative development process in the design and
65 implementation of these tools required to meet the needs of clinicians to improve uptake and quality of
66 care. We considered the feasibility, acceptability and reliability of clinical signs and symptoms, as well
67 as the diagnostic and prognostic performance of predictors. To assure clinical validity, and
68 appropriateness for the country of implementation the algorithm underwent numerous reviews by
69 clinical experts and health authorities from the implementing countries. The digitalization process
70 involved the creation of *medAL-creator*, a digital platform which allows clinicians without IT skills to
71 easily create the algorithms, and *medAL-reader* the mobile health (mHealth) app used by clinicians
72 during the consultation. Extensive feasibility tests were done with feedback from end-users of multiple
73 countries to improve the clinical algorithm and *medAL-reader* software.

74 We hope that the development framework used for developing ePOCT+ will help support the
75 development of other CDSAs, and that the open-source *medAL-suite* will enable others to easily and
76 independently implement them.

77 **AUTHOR SUMMARY**

78 In accordance with the principles of digital development we describe here the process and lessons
79 learnt from the development of ePOCT+, a clinical decision support algorithm (CDSA), and the
80 medAL-suite software, to program and implement CDSAs.

81 The clinical algorithm was adapted from previous CDSAs in order to address challenges in regards to
82 the limited scope of illnesses and patient population addressed, the ease of use, and limited
83 performance of specific algorithms. Adaptations and improvements to the clinical algorithm was
84 developed based on considerations of what symptoms and signs would be appropriate for primary
85 care level health care workers, and how well these clinical elements are at predicting a particular
86 disease or severe outcome. We hope that by sharing our multi-stakeholder approach to the
87 development of ePOCT+, it can help others in the development of other CDSAs.

88 The medAL-*creator* software was developed to allow clinicians without IT programming experience to
89 program the clinical algorithm using a drag-and-drop interface, which we hope allows a wider range of
90 health authorities and implementers to develop and adapt their own CDSA. The medAL-*reader*
91 application, deploys the algorithm from medAL-*creator* to end-users following the usual healthcare
92 processes of a consultation.

93


94

95 INTRODUCTION

96 Electronic clinical decision support algorithms (CDSAs) have been implemented in low- and middle-
97 income countries (LMICs) in order to address excessive mortality due to poor quality of health care,[1]
98 and antimicrobial resistance due to inappropriate antibiotic prescription.[2-4] Such tools provide
99 guidance through every step of the outpatient consultation to ultimately suggest the diagnosis and
100 management plan based on the inputted symptoms, signs and test results.[5] CDSAs have indeed
101 shown that they help clinicians better adhere to guidelines,[6-8] which results in improved quality of
102 care and, for some, more rational antibiotic prescription.[9, 10] This has, in part led the World Health
103 Organization (WHO) and Member States to prioritize the scale-up of the development and access to
104 digital health technologies.[11, 12]

105 Current CDSAs are not standardized, and concerns have been raised about their limited demographic
106 and clinical scope,[13, 14] their usability,[14, 15] and their static and generic logic based on outdated
107 guidelines that are unable to adapt to new evidence, evolving epidemiology, or changing resources.
108 These challenges may contribute to variable uptake of CDSAs,[15-17] and suboptimal performance
109 when implemented.[8, 18]

110 In order to address these challenges, and build on the experience of previous CDSAs by our group,[9,
111 10] and others,[5, 8] we developed the CDSA ePOCT+, and a supporting digital software to create and
112 execute CDSAs, the *medAL-suite*. ePOCT+ is currently being implemented in several hundred health
113 facilities within the context of implementation studies in Tanzania, Rwanda, Senegal, Kenya and India.
114 Following the principles of digital development and guidance on CDSAs,[19-21] we aim to
115 transparently share the rationale, strategy, and lessons learnt from this development process (figure
116 1).



117

118 **Figure 1: Overall development process of ePOCT+ requiring multiple feedback loops**

119 The development process of ePOCT+ was an iterative process. We first defined the scope, then developed the
120 algorithm (decision tree logic), followed by expert review with relevant stakeholders, the digitalization, and finally
121 piloting and testing. Each stage resulted in multiple feedback loops to refine the end product.

122

123

124 **METHODS**

125

126 **Scope**

127 Compared to our previous generation CDSAs,[5, 9, 10] the target level of care (primary care health
128 facilities), and target users (mostly nurses and non-physician clinicians) remain the same. However,
129 the target patient population was expanded from 2 months to 5 years, to also cover young infants
130 below 2 months, and in some countries children 5 years up to 15 years.

131

132 The expanded target population age group was enlarged to address young infants (<2 months) who
133 are at highest risk of mortality,[22] and children aged 5-15 years whom are often neglected in
134 international and national policies resulting in a slower decrease in mortality in LMICs compared to
135 children under 5 years.[23] This expanded age group may help address the challenge of uptake by
136 avoiding the need for clinicians to change tools when managing children of different age groups.

137 The scope of illnesses covered was also expanded in response to the frustration of clinicians using
138 CDSAs who were not able to reach specific illnesses.[13, 15] Expanding the scope allowed for the
139 integration of common illnesses covered by other national clinical guidelines to which clinicians are
140 expected to adhere, and to provide more opportunity for antibiotic stewardship when providing
141 management guidance for specific illnesses.

142 Three major criteria were considered when expanding the scope of illnesses: 1) Incidence of
143 presenting symptoms and diagnoses; 2) Morbidity, mortality, and outbreak potential; and 3) Capacity
144 to diagnose and manage specific conditions at the primary care level.

145 Additional conditions were identified through: 1) national guidelines; 2) fever aetiology studies; 3)
146 national health surveys; 4) chief complaints from primary care outpatient studies; 5) clinical expert
147 review teams from the implementation countries; 6) interviews with end user clinicians; and 6)
148 observation of consultations at primary care health facilities (S1 Appendix). Examples of notable
149 additions for the Tanzanian algorithm include trauma, urinary tract infection, and abdominal pain that
150 can account for 4.3 – 21.6%,[24] 5.9 – 19.7%,[24-26] and 4.6 – 23%[10, 25] of outpatient
151 consultations respectively.

152 **Clinical algorithm**

153 The target users (mostly nurses and non-physician clinicians), and setting (primary care health
154 facilities) were important considerations when identifying the guidelines and evidence to develop the
155 algorithm. Previously validated algorithms,[10] and the WHO Integrated Management of Childhood
156 Illnesses (IMCI) chart booklets formed the backbone of the algorithm.[27] To support the expanded
157 clinical scope, we turned to national guidelines to ensure adaptation to the local epidemiology,
158 resources, and setting. For conditions not covered by these guidelines, or where guidelines were not
159 sufficiently detailed, the addition of peer-reviewed literature and other international guidelines were
160 required.

161 In order to transform narrative guidelines into Boolean decision tree logic algorithms, considerable
162 interpretation was needed. The guiding principles for this process were derived from the properties to
163 consider in the screening and diagnosis of a disease by Sackett and colleagues,[28] the target product
164 profile (TPP) for CDSAs as defined by experts in the field,[20] and guidance on appropriate diagnostic
165 and prognostic model development.[29] These include consideration of: a) the feasibility, acceptability,
166 and reliability of clinical elements assessed at the primary care level, b) the diagnostic and prognostic
167 value of individual and combined predictors, c) the sensitivity and specificity in relation to the severity
168 and pre-test probability of the condition in the target population, and d) the overall clinical impression
169 of the patient by the clinician.

170 a) Feasibility, acceptability, and reliability of predictors

171 If clinical algorithms are to be adequately utilized, the signs and symptoms used to reach a diagnosis
172 must be feasible, acceptable and reliable when assessed by end-users. These properties were
173 evaluated based on the results of several assessments: primarily an international Delphi study on
174 predictors of sepsis in children,[30] a systematic review on triage tools in low-resource settings,[31]
175 signs and symptoms included in established guidelines for primary care health care workers such as
176 IMCI,[27] interviews with clinicians, observation of routine consultations, a Delphi survey among 30
177 Tanzanian health care workers (S2 Appendix), as well as subsequent feasibility tests observing
178 clinicians using the CDSA on real and fictional cases. Notable findings from this process led to the
179 omission of a pain score, capillary refill time, the assessment of cool peripheries, and weak and fast
180 pulse, as they were deemed neither feasible nor reliable to be assessed at the primary care level.

181 b) Diagnostic and prognostic value of predictors


182 In the absence of validated diagnostic models for each diagnosis, we assessed individual diagnostic
183 and prognostic factors to help guide the development of ePOCT+. Diagnostic studies derived from the
184 population and setting of interest were preferred,[32, 33] as those developed from other settings often
185 perform worse.[34] However, diagnostic predictors notably those predicting ‘serious bacterial
186 infection’, often have low sensitivity, lack reference tests to confirm bacterial origin, and ignore serious
187 infections caused by viral diseases.[35, 36] Prognostic studies are often better suited to develop
188 clinical algorithms in order to understand which children are at risk of developing severe disease,
189 regardless of the aetiology, to improve patient outcomes and reduce resource misallocation. [37-39] A
190 systematic review of predictors of severe disease in febrile children presenting from the community
191 helped identify useful clinical feature to be integrated within ePOCT+,[34] however few studies
192 occurred at the primary care level. To address this gap we performed an exploratory analysis of
193 clinical elements used in two CDSAs evaluated in Tanzania to predict clinical failure (S3 Appendix).
194 This analysis found IMCI danger signs, severe general appearance, mid-upper arm circumference
195 <12.5cm, oxygen saturation <90%, respiratory distress, and signs of anaemia and dehydration to be
196 good predictors of clinical failure. Specific subgroup analyses on our previous generation CDSA
197 provided further support for maintaining or modifying specific algorithm branches, particularly the
198 inclusion of C-reactive Protein (CRP) point-of-care tests that helped safely reduce antibiotic
199 prescription and improve confidence in management.[40, 41]

200 c) Sensitivity and specificity of algorithm branches in relation to severity and pre-test probability of
201 condition

202 When constructing the algorithm, it was important to first identify children presenting with a severe
203 condition, and only then use more specific branches to distinguish conditions requiring specific
204 treatment from self-limiting illnesses requiring only supportive care (figure 2). Predictors of severe
205 conditions need to be sufficiently sensitive to guide interventions to reduce morbidity and mortality.
206 However if this high sensitivity comes at the cost of reduced specificity, it can result in over-referral,
207 misallocation of limited health care resources, and excess antibiotic prescription.[37] While this
208 concept was considered within the development of the algorithm, most predictors and models studied
209 lacked sufficient sensitivity and specificity to appropriately meet these requirements at the primary
210 care level, thus emphasizing the need for better predictors and models.[34, 37]

211 Once a severe condition has been excluded, restricting antimicrobial prescriptions can be more safely
212 integrated given the lower risk of clinical failure. Understanding the pre-test probability (disease
213 prevalence) of the disease guides us on the level of specificity needed for the corresponding
214 predictors to be included in the algorithm. In the outpatient settings, few non-severe children above 2
215 months have a condition requiring antibiotics.[10, 26] As such, using the principles of Bayes'
216 theorem,[42] an algorithm for a condition of low prevalence requires a higher likelihood ratio to have a
217 similar post-test probability than a condition with a higher prevalence. Within ePOCT+, C-Reactive
218 Protein (CRP) test is integrated in several branches of the algorithm to increase specificity/likelihood
219 ratio when the pre-test probability of requiring antibiotics is low. However, the pre-test probability of
220 requiring antibiotics may increase in a child with comorbidities, and therefore a lower CRP cut-off can
221 be used to increase sensitivity and reach the same post-test probability.

222



224

224 **Figure 2: Considerations for the required sensitivity and specificity of combined predictors**
225 **based on the severity and the pre-test probability (disease prevalence) of the condition**

226 Health care workers are confronted with two major questions at primary care health facilities: 1) Does the child
227 need to be referred? For which an algorithm must evaluate sensitivity and specificity in relation to the severity of
228 disease. 2) Does the child require specific treatment (most often an antibiotic)? For which the disease prevalence
229 of a bacterial illness needs to be considered when evaluating the sensitivity and specificity of such an algorithm.

230

231 d) Integrating overall clinical impression

232 The overall clinical impression of a healthcare worker plays an important part of the diagnostic
233 process,[43] and may sometimes better identify serious conditions compared to isolated symptoms
234 and signs.[44, 45] As blindly following CDSA recommendations runs the risk of neglecting nuanced
235 clinical observations or patient-initiated elements, we incorporated clinical impression in the algorithm
236 to better preserve these skills.[46] More generally, it also shows a respect and consideration for the
237 clinician's judgment and allows the tools to be more participatory; including the clinician in the
238 interpretation and responsibility of the decision. As such, attempts were made to combine multiple
239 clinical elements into one question utilizing clinical impression. This approach was used to help identify
240 children who need a referral or antibiotics, such as "Severe difficult breathing needing referral", a
241 criteria similar to that proposed by the British Thoracic Society,[47] and "well/unwell appearing child",
242 often used in children with fever without apparent source.[35, 48] Highlighting in the application that
243 this response will result in a recommendation of referral, aims to help clinicians understand the impact
244 of their selection, and thus improve both the sensitivity and specificity. Such composite elements
245 reduce the number of questions prompted by the CDSA, and speeds up the process; an important
246 consideration for uptake. Nevertheless, the diagnostic and prognostic value of the overall clinical
247 impression of primary care clinicians in LMIC settings is not well understood, and further research is
248 needed to understand how helpful these types of elements are when integrated within ePOCT+.

249

250 **Adapting and validating the medical content**

251 ePOCT+ was first developed for Tanzania, where the prior generation of the algorithm was validated
252 in a randomized-controlled trial.[10] Following the expansion and adaptation of the content described
253 above, the algorithm was internally reviewed by 13 clinicians from 6 medical institutions with good
254 understanding of CDSAs; 5 working in Tanzania, and the other 8 with experience working in LMICs.
255 The ePOCT+ algorithm for Rwanda, Senegal, Kenya and India were then each drafted, with rounds of
256 internal review, by small development teams composed of clinical algorithm development specialists,
257 and national child health experts based on country-specific objectives, guidelines, and epidemiology,
258 using the first algorithm as a scaffold.

259 In each country, the ePOCT+ algorithm was reviewed by a technical panel from the ministry of health
260 or an independent clinical expert group (usually with ministry of health representatives). The panels
261 were asked to assess the algorithm in terms of clinical validity, feasibility in primary care, scope of

262 illnesses, and consistency with national policy and guidelines. The process of validation varied slightly
263 in each country according to national decision-making mechanisms, but all included written feedback,
264 individual and group meetings.


265 Certain algorithm branches were highlighted for group discussion; especially those with novel content,
266 those for which significant interpretation was required from national guidelines, and any branches with
267 queries or comments from panel members. For the algorithms with more novel content, more formal
268 decision processes were used.

269 Following the internal and external reviews, further modifications were made during the digitalization
270 process, and feasibility tests, including feedback and review from end-users. For each major change
271 proposed, the modification was communicated with the group to allow subsequent feedback and final
272 approval by health authorities

273 **Digitalization of ePOCT+ and development of the medAL-suite**

274 We performed a landscaping review of existing CDSA software with respect to user interface, open
275 source, data management, ease of programming and interpretation of clinical algorithms, and
276 operability in target health facilities. Since none of the available software packages met our
277 requirements, we developed the medAL-suite software following the requirements of the target product
278 profile for CDSAs.[20] [medAL-creator](#) allows clinical experts to design the clinical content and logic of
279 the algorithm, while [medAL-reader](#) is an Android based interface to execute the algorithm to end-user
280 clinicians (figure 3). Both software were developed collaboratively between the clinicians, IT
281 programmers, end-users via feedback from field tests, and health authorities from the implementation

282 countries.



283

284 **Figure 3: medAL-creator and medAL-reader**

285 A) medAL-creator and its “drag and drop” user interface to design the clinical algorithm. For each clinical element
286 a description and/or photo can be included to assist the end-user using medAL-reader ; B) medAL-reader the
287 android based application to collect the medical history, exposures, symptoms, signs and tests, and then propose
288 the appropriate diagnosis and management.

289

290 The World Health Organization (WHO) have recently proposed the SMART guidelines to provide
291 guidance and structure to translate the narrative guidelines (Layer 1), to semi-structured “human
292 readable” decision trees and digital adaptation kits (Layer 2), to computer/machine readable structured
293 algorithms (Layer 3), to the executable form of the software (Layer 4), and finally dynamic algorithms
294 that are trained and optimised to local data (Layer 5).[49] Each “translation” between layers is prone to
295 interpretation and error, especially when each layer is developed by different actors and continuously
296 adapted. To reduce error in interpretation, a major feature of medAL-creator is to allow the
297 “computer/machine readable” structured algorithms to be “human readable”, thus merging Layers 2
298 and 3. medAL-creator features a “drag and drop” user interface and automatic terminology/code set
299 enabling the clinicians with no programming knowledge to create and review the algorithm. medAL-
300 reader is then able to automatically convert the algorithm from medAL-creator for use at point-of-care.

301 medAL-reader, was designed based on our previous experiences of CDSA interfaces,[7, 10] and
302 expert guidance on successful strategies in order for the application to be intuitive to use with limited
303 training, to align with normal workflows at primary care health facilities, and encourage user
304 autonomy.[20, 50, 51]

305 **Validation tests and user-experience evaluations**

306 Validation tests were performed for each diagnosis to assure that the inputted data within medAL-
307 *creator* were processed correctly into the expected output data on medAL-*reader*. This included
308 automated unit and integration testing, as well as automated non-regression testing by medAL-*creator*,
309 and manual verification of medication posology for all drugs according to weight and age of the
310 patient. All issues were reviewed by a clinical and IT team to correct the problems. While such tests
311 are encouraged by the CDSA TPP,[20] since CDSAs are not considered a “software as a medical
312 device ” by the Food and Drug Administration (FDA)[52] or European Medical Device Coordination
313 Group,[53] these tests are not legally required.

314 The ePOCT+ tool underwent numerous rounds of testing in the field, from desk-based reviews
315 focusing on user interface and analytical validation; to end-user testing evaluating user experience,
316 acceptability, and clinical applicability; to finally assessing integrated testing in real-life conditions. All
317 user experience feedback was reviewed by a team including both clinical and IT specialists, while all
318 clinical content modifications were approved by both the internal and external review panels.

319

320 **Ethics**

321 Activities related to the development and piloting of ePOCT+ and the medAL-suite were done within
322 the studies of DYNAMIC and TIMCI, for which approval was given from each country of
323 implementation. The study protocol and related documents were approved by the institutional review
324 boards of the Ifakara Health Institute in Tanzania (IHI/IRB/No: 11-2020 and 49-2020), the National
325 Institute for Medical Research in Tanzania (NIMR/HQ/R.8a/Vol. IX/3486 and NIMR/HQ/R.8a/Vol.
326 IX/3583), the National Ethics Committee of Rwanda (752/RNEC/2020), the Comité National d’Ethique
327 pour la Recherche en Santé of Senegal (SEN20/50), the University of Nairobi Ethics and Research
328 Committee in Kenya (UON/CHS/TIMCI/1/1), the King George’s Medical College Institutional Ethics
329 Committee in India (103rd ECM IC/P2), the Indian Council of Medical Research (2020-9753), the
330 cantonal ethics review board of Vaud, Switzerland (CER-VD 2020-02800 & CER-VD 2020-02799),
331 and the WHO Ethics Review Committee (ERC.0003405 & ERC.0003406). Written informed consent
332 was obtained from all parents or guardians of children involved in the piloting of ePOCT+ and medAL-
333 *Reader*. No informed consent was obtained from health care workers involved in the development and
334 refinement of the tools.

335 The exploratory analysis of predictors from the 2014 ePOCT study received approval of the study
336 protocol and related documents by the institutional review boards of the Ifakara Health Institute and
337 the National Institute for Medical Research in Tanzania (NIMRrHQ,R.8a,/trl'Voll . 789), by the
338 Ethikkommission Beider Basel in Switzerland (EKNZ UBE 15/03), and the Boston Children's Hospital
339 ethical review board. Written informed consent was obtained from all parents or guardians.

340

341 RESULTS

342 The ePOCT+ clinical algorithm and supporting evidence for each country of implementation can be
343 found on the websites of the [DYNAMIC](#) and [TIMCI](#) studies that are implementing ePOCT+. The major
344 features of *medAL-Creator* and *medAL-Reader* are summarized in the supplementary material (S4
345 Appendix), including the requirements defined by the CDSA target product profile (S5 Appendix).

346 The feasibility tests of ePOCT+ were conducted in 20 health facilities, leading to numerous
347 modifications (Table 1). The improved algorithm was then piloted with over 2000 consultations before
348 officially starting the clinical validation studies in the five countries of implementation.

349

350 **Table 1. Example of modifications based on user-experience feedback and observations**

Issue	Description + context	Modifications
CDSA impractical in emergency situations	Child with convulsions was brought into the consultation room interrupting the current consultation. The clinician stopped using the tablet and managed the child providing the incorrect antibiotic class and dose	Emergency button integrated so that emergency management guidance can easily be accessed at any point of the algorithm.
Understanding algorithm branches	Why a patient reached a specific diagnosis was not always well understood by clinicians	To improve understanding, and to have medAL-reader as a learning tool, efforts were made to simply present the decision tree logic for individual diagnostic and syndromic branches of the algorithm.
Some medicines not available at health	Sometimes medicines recommended by national guidelines were not available	Provide alternative medicines for most conditions in case the recommended one is not available.

facilities due to stock-outs		
Misunderstanding of the labelling of some clinical elements	The labelling of some symptoms and signs were not well understood by the clinician	Modification of labelling of some elements, clarification provided in the information button, and translation to local language
Some clinical signs not measured, especially when patients are many	Many clinicians did not always measure required clinical signs (anthropometrics, temperature, respiratory rate) and could thus not continue with the algorithm	Provide options to not measure some clinical signs and rather estimate the values (with warning that this is sub-optimal) to limit clinicians being 'stuck', to discourage false information to be entered, and to provide mentorship to those not measuring these signs
No clear identification of symptoms and signs that always result in severe disease / referral	Clinicians selected variables that resulted in a severe diagnosis, parenteral antibiotics, and referral, for which the clinician did not agree with.	Elements that result in the diagnosis of a severe disease and referral are highlighted

351

352 **DISCUSSION**

353 ePOCT+ was derived from existing evidence and clinical validation field studies from previous
 354 generation CDSAs.[7, 9, 10] It is now being further validated in several large clinical studies. Following
 355 established development protocols, attempts were made to ensure a transparent development
 356 process, multi-stakeholder collaboration, and end-user feedback.[20, 21, 54, 55] Specifically, aligning
 357 the development process of ePOCT+ and specifications of medAL-*reader* to the requirements of the
 358 Target Product Profile for CDSAs was helpful to better meet the needs of end users in terms of quality,
 359 safety, performance and operational functionality.[20]. Nonetheless, there are several limitations and
 360 challenges with the development process and end-result of ePOCT+ and the medAL-*suite*, for which
 361 ongoing modifications and improvements will be required.

362 Firstly, while efforts were made to improve the performance of the algorithm, there was often a
 363 reliance on clinical guidelines which may not always be founded on the best/latest/highest quality

364 evidence, or applicable to low resource primary care settings.[56] [57] Furthermore, they require
365 significant interpretation to transform into algorithms. Digital Adaptation Kits (DAKs) to guide
366 implementers in how to interpret narrative guidelines to transform into digital platforms are currently
367 being developed by the World Health Organization and should help address this challenge in the
368 future.[49, 58] Often supplementary evidence was needed to complement national and international
369 guidelines. This evidence should ideally be identified through systematic reviews,[59] however those
370 are not always feasible. Leveraging existing evidence databases as done by another CDSA may be a
371 more feasible method to avoid biases in identifying supporting evidence.[60] Among the supporting
372 evidence identified, there was a paucity of evidence for conditions specific to older children above 5
373 years, prognostic studies in the primary care setting, and diagnostic studies for conditions other than
374 serious bacterial infection and pneumonia. Evaluating the prognostic and diagnostic value of
375 predictors and models used in ePOCT+ during the ongoing validation studies will help to develop more
376 efficient and better performing algorithms optimised for the target population.[49, 61]

377 Many modifications to ePOCT+ and *medAL-reader* compared to previous generation CDSAs were
378 implemented in order to help improve uptake, addressing previously shared concerns such as limited
379 scope, and ease of use. *medAL-reader* was specifically designed to follow normal healthcare worker
380 workflows, however the introduction of other digital tools such as electronic medical records hinder
381 these processes. As an example, it is estimated that there are over 160 digital health or health-related
382 systems in Tanzania.[62] While efforts are currently being made to harmonize processes so that
383 different digital systems can complement each other, rather than creating additional work, this has not
384 yet been achieved. It is important to note, that while ePOCT+ and *medAL-reader* may address some
385 challenges to uptake, there are many extrinsic and intrinsic factors that are not addressed, such as the
386 low perceived value of following guidelines, and lack of motivation partly related to poor
387 remuneration.[15, 63]

388 The digitalization process allows for increased complexity in the algorithm compared to paper
389 guidelines. However, this complexity may limit the understanding by healthcare workers.
390 Understanding how a diagnosis and treatment plan is reached is fundamental to clinical and patient
391 autonomy, important for continued learning, and for fostering trust in any algorithm.[64-66] Efforts were
392 made to present simple decision tree logic for each diagnosis. Nevertheless, the optimal method of

393 presentation of algorithm branches to assure understanding by primary care level healthcare workers

394 should be further explored.

395

396 **CONCLUSION**

397 ePOCT+ aims to improve clinical care of sick children in LMICs, notably by reducing unnecessary
398 antibiotic prescription. We hope that the strong stakeholder involvement, the expanded scope of the
399 clinical algorithm, and the novel software of the *medAL-suite* will result in high uptake, trust and
400 acceptability. Widespread implementation will provide opportunity for dynamic and targeted
401 refinements to the clinical content to improve the performance of the algorithm. We hope that the
402 easy-to-use platform of the *medAL-suite*, and the framework used to develop ePOCT+ will allow
403 health authorities and local communities to be able to take ownership of ePOCT+ or their own clinical
404 algorithm for future adaptations and developments. Future success however, is contingent on the
405 harmonization with national health management information systems and other digital systems.

406

407

408 **Declaration of interests:**

409 We declare no competing interests.

410

411 **Funding**

412 This work took place within the framework of the DYNAMIC project that is funded by the [Fondation](#)
413 [Botnar](#), Switzerland (grant n°6278) as well as the [Swiss Development Cooperation](#) (grant n°7F-
414 10361.01.01) received by VDA. The TIMCI project funded by [UNITAID](#) (grant n°2019-35-TIMCI)
415 received by VDA allowed for adapting of ePOCT+ or the medAL-suite software to Senegal, Kenya and
416 India. The funders had no role in the development of ePOCT+ or the medAL-suite software, data
417 collection, analysis, nor did they have a role in the decision to publish, or preparation of this
418 manuscript.

419

420 **Acknowledgements:**

421 Emmanuel Barchichat, Alain Fresco, and Quentin Girard from Wavemind for the IT programming of
422 medal-creator and medal-reader software. Martin Norris, Lisa Cleveley, Dr Sabine Renggli, Ibrahim
423 Mtabene, Peter Agrea and Dr Godfrey Kavishe for the medAL-reader tests and suggestions for
424 improvements to both medal-reader and medal-creator. Cecile Trottet for the statistical support. The
425 many health care workers providing feedback on the tool, patients and caretakers involved with pilot
426 and feasibility testing. Dr Arjun Chandna and Janet Urquhart for helpful comments on the manuscript.

427

428 REFERENCES

- 429 1. Kruk ME, Gage AD, Joseph NT, Danaei G, García-Saisó S, Salomon JA. Mortality
430 due to low-quality health systems in the universal health coverage era: a systematic analysis
431 of amenable deaths in 137 countries. *The Lancet*. 2018;392(10160):2203-12. doi:
432 10.1016/S0140-6736(18)31668-4.
- 433 2. Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al.
434 Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *The*
435 *Lancet*. 2022. doi: 10.1016/S0140-6736(21)02724-0.
- 436 3. Fink G, D'Acremont V, Leslie H, Cohen J. Antibiotic use among children under five in
437 low and middle income countries: Evidence from nationally representative facility and
438 household surveys. *Lancet Infectious Diseases*. in press.
- 439 4. van de Maat J, De Santis O, Luwanda L, Tan R, Keitel K. Primary Care Case
440 Management of Febrile Children: Insights From the ePOCT Routine Care Cohort in Dar es
441 Salaam, Tanzania. *Frontiers in pediatrics*. 2021;9(465). doi: 10.3389/fped.2021.626386.
- 442 5. Keitel K, D'Acremont V. Electronic clinical decision algorithms for the integrated
443 primary care management of febrile children in low-resource settings: review of existing
444 tools. *Clinical microbiology and infection : the official publication of the European Society of*
445 *Clinical Microbiology and Infectious Diseases*. 2018;24(8):845-55. Epub 2018/04/24. doi:
446 10.1016/j.cmi.2018.04.014. PubMed PMID: 29684634.
- 447 6. Bernasconi A, Crabbé F, Raab M, Rossi R. Can the use of digital algorithms improve
448 quality care? An example from Afghanistan. *PLoS One*. 2018;13(11):e0207233-e. doi:
449 10.1371/journal.pone.0207233. PubMed PMID: 30475833.
- 450 7. Rambaud-Althaus C, Shao A, Samaka J, Swai N, Perri S, Kahama-Maró J, et al.
451 Performance of Health Workers Using an Electronic Algorithm for the Management of
452 Childhood Illness in Tanzania: A Pilot Implementation Study. *The American journal of tropical*
453 *medicine and hygiene*. 2017;96(1):249-57. Epub 2017/01/13. doi: 10.4269/ajtmh.15-0395.
454 PubMed PMID: 28077751; PubMed Central PMCID: PMC5239703.
- 455 8. Sarrassat S, Lewis JJ, Some AS, Somda S, Cousens S, Blanchet K. An Integrated
456 eDiagnosis Approach (leDA) versus standard IMCI for assessing and managing childhood
457 illness in Burkina Faso: a stepped-wedge cluster randomised trial. *BMC health services*
458 *research*. 2021;21(1):354-. doi: 10.1186/s12913-021-06317-3. PubMed PMID: 33863326.
- 459 9. Shao AF, Rambaud-Althaus C, Samaka J, Faustine AF, Perri-Moore S, Swai N, et al.
460 New Algorithm for Managing Childhood Illness Using Mobile Technology (ALMANACH): A
461 Controlled Non-Inferiority Study on Clinical Outcome and Antibiotic Use in Tanzania. *PLoS*
462 *One*. 2015;10(7):e0132316. Epub 2015/07/15. doi: 10.1371/journal.pone.0132316. PubMed
463 PMID: 26161535; PubMed Central PMCID: PMC4498627.
- 464 10. Keitel K, Kagoro F, Samaka J, Masimba J, Said Z, Temba H, et al. A novel electronic
465 algorithm using host biomarker point-of-care tests for the management of febrile illnesses in
466 Tanzanian children (e-POCT): A randomized, controlled non-inferiority trial. *PLoS medicine*.
467 2017;14(10):e1002411. Epub 2017/10/24. doi: 10.1371/journal.pmed.1002411. PubMed
468 PMID: 29059253; PubMed Central PMCID: PMC45653205.
- 469 11. World Health Organization. WHO guideline: recommendations on digital interventions
470 for health system strengthening. Geneva: 2019 Contract No.: Licence: CC BY-NC-SA 3.0
471 IGO.
- 472 12. United Republic of Tanzania: Ministry of Health CD, Gender, Elderly and Children.
473 Digital Health Strategy. Tanzania: 2019.
- 474 13. Bessat C, Zonon NA, D'Acremont V. Large-scale implementation of electronic
475 Integrated Management of Childhood Illness (eIMCI) at the primary care level in Burkina
476 Faso: a qualitative study on health worker perception of its medical content, usability and
477 impact on antibiotic prescription and resistance. *BMC public health*. 2019;19(1):449. Epub
478 2019/05/01. doi: 10.1186/s12889-019-6692-6. PubMed PMID: 31035968; PubMed Central
479 PMCID: PMC6489291.
- 480 14. Mitchell M, Getchell M, Nkaka M, Msellemu D, Van Esch J, Hedt-Gauthier B.
481 Perceived Improvement in Integrated Management of Childhood Illness Implementation

- 482 through Use of Mobile Technology: Qualitative Evidence From a Pilot Study in Tanzania.
483 Journal of Health Communication. 2012;17(sup1):118-27. doi:
484 10.1080/10810730.2011.649105.
- 485 15. Shao AF, Rambaud-Althaus C, Swai N, Kahama-Maró J, Genton B, D'Acremont V, et
486 al. Can smartphones and tablets improve the management of childhood illness in Tanzania?
487 A qualitative study from a primary health care worker's perspective. BMC health services
488 research. 2015;15:135-. doi: 10.1186/s12913-015-0805-4. PubMed PMID: 25890078.
- 489 16. Jensen C, McKerrow NH, Wills G. Acceptability and uptake of an electronic decision-
490 making tool to support the implementation of IMCI in primary healthcare facilities in KwaZulu-
491 Natal, South Africa. Paediatr Int Child Health. 2020;40(4):215-26. Epub 2019/11/30. doi:
492 10.1080/20469047.2019.1697573. PubMed PMID: 31779539.
- 493 17. Jensen C, McKerrow NH. The feasibility and ongoing use of electronic decision
494 support to strengthen the implementation of IMCI in KwaZulu-Natal, South Africa. BMC
495 Pediatrics. 2022;22(1):80. doi: 10.1186/s12887-022-03147-y.
- 496 18. Bernasconi A, Crabbé F, Adedeji AM, Bello A, Schmitz T, Landi M, et al. Results from
497 one-year use of an electronic Clinical Decision Support System in a post-conflict context: An
498 implementation research. PLoS One. 2019;14(12):e0225634. Epub 2019/12/04. doi:
499 10.1371/journal.pone.0225634. PubMed PMID: 31790448; PubMed Central PMCID:
500 PMC6886837.
- 501 19. Waugaman A. From principle to practice: implementing the principles for digital
502 development. Proceedings of the Principles for Digital Development Working Group. 2016;4.
- 503 20. Pellé KG, Rambaud-Althaus C, Acremont V, Moran G, Sampath R, Katz Z, et al.
504 Electronic clinical decision support algorithms incorporating point-of-care diagnostic tests in
505 low-resource settings: a target product profile. BMJ Global Health. 2020;5(2):e002067. doi:
506 10.1136/bmjgh-2019-002067.
- 507 21. Ansermino JM, Wiens MO, Kisson N. Evidence and Transparency are Needed to
508 Develop a Frontline Health Worker mHealth Assessment Platform. 2019;101(4):948-. doi:
509 <https://doi.org/10.4269/ajtmh.19-0411a>.
- 510 22. Li Z, Karlsson O, Kim R, Subramanian SV. Distribution of under-5 deaths in the
511 neonatal, postneonatal, and childhood periods: a multicountry analysis in 64 low- and middle-
512 income countries. Int J Equity Health. 2021;20(1):109-. doi: 10.1186/s12939-021-01449-8.
513 PubMed PMID: 33902593.
- 514 23. Masquelier B, Hug L, Sharrow D, You D, Hogan D, Hill K, et al. Global, regional, and
515 national mortality trends in older children and young adolescents (5–14 years) from 1990 to
516 2016: an analysis of empirical data. The Lancet Global Health. 2018;6(10):e1087-e99. doi:
517 [https://doi.org/10.1016/S2214-109X\(18\)30353-X](https://doi.org/10.1016/S2214-109X(18)30353-X).
- 518 24. McHomvu E, Mbunda G, Simon N, Kitila F, Temba Y, Msumba I, et al. Diagnoses
519 made in an Emergency Department in rural sub-Saharan Africa. Swiss Med Wkly.
520 2019;149:w20018. Epub 2019/02/05. doi: 10.4414/smw.2019.20018. PubMed PMID:
521 30715723.
- 522 25. Hercik C, Cosmas L, Mogeni OD, Wamola N, Kohi W, Omballa V, et al. A diagnostic
523 and epidemiologic investigation of acute febrile illness (AFI) in Kilombero, Tanzania. PLoS
524 One. 2017;12(12):e0189712-e. doi: 10.1371/journal.pone.0189712. PubMed PMID:
525 29287070.
- 526 26. D'Acremont V, Kilowoko M, Kyungu E, Philipina S, Sangu W, Kahama-Maró J, et al.
527 Beyond malaria--causes of fever in outpatient Tanzanian children. The New England journal
528 of medicine. 2014;370(9):809-17. Epub 2014/02/28. doi: 10.1056/NEJMoa1214482. PubMed
529 PMID: 24571753.
- 530 27. World Health Organization. IMCI chart booklet. Geneva: 2014.
- 531 28. Sackett DL, Holland WW. Controversy in the detection of disease. Lancet.
532 1975;2(7930):357-9. Epub 1975/08/23. doi: 10.1016/s0140-6736(75)92790-7. PubMed
533 PMID: 51154.
- 534 29. Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, Macaskill P, Steyerberg EW, et
535 al. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or
536 Diagnosis (TRIPOD): Explanation and Elaboration. Annals of internal medicine.
537 2015;162(1):W1-W73. doi: 10.7326/M14-0698 %J Annals of Internal Medicine.

- 538 30. Fung JST, Akech S, Kissoon N, Wiens MO, English M, Ansermino JM. Determining
539 predictors of sepsis at triage among children under 5 years of age in resource-limited
540 settings: A modified Delphi process. *PLoS One*. 2019;14(1):e0211274. Epub 2019/01/29.
541 doi: 10.1371/journal.pone.0211274. PubMed PMID: 30689660; PubMed Central PMCID:
542 PMCPMC6349330.
- 543 31. Hansoti B, Jenson A, Keefe D, De Ramirez SS, Anest T, Twomey M, et al. Reliability
544 and validity of pediatric triage tools evaluated in Low resource settings: a systematic review.
545 *BMC Pediatrics*. 2017;17(1):37. doi: 10.1186/s12887-017-0796-x.
- 546 32. Erdman LK, D'Acremont V, Hayford K, Rajwans N, Kilowoko M, Kyungu E, et al.
547 Biomarkers of Host Response Predict Primary End-Point Radiological Pneumonia in
548 Tanzanian Children with Clinical Pneumonia: A Prospective Cohort Study. *PLoS One*.
549 2015;10(9):e0137592. Epub 2015/09/15. doi: 10.1371/journal.pone.0137592. PubMed PMID:
550 26366571; PubMed Central PMCID: PMCPMC4569067.
- 551 33. De Santis O, Kilowoko M, Kyungu E, Sangu W, Cherpillod P, Kaiser L, et al.
552 Predictive value of clinical and laboratory features for the main febrile diseases in children
553 living in Tanzania: A prospective observational study. *PLoS One*. 2017;12(5):e0173314.
554 Epub 2017/05/04. doi: 10.1371/journal.pone.0173314. PubMed PMID: 28464021; PubMed
555 Central PMCID: PMCPMC5413055.
- 556 34. Chandna A, Tan R, Carter M, Van Den Bruel A, Verbakel J, Koshiaris C, et al.
557 Predictors of disease severity in children presenting from the community with febrile
558 illnesses: a systematic review of prognostic studies. *BMJ Glob Health*. 2021;6(1). Epub
559 2021/01/22. doi: 10.1136/bmjgh-2020-003451. PubMed PMID: 33472837.
- 560 35. Keitel K, Kilowoko M, Kyungu E, Genton B, D'Acremont V. Performance of prediction
561 rules and guidelines in detecting serious bacterial infections among Tanzanian febrile
562 children. *BMC infectious diseases*. 2019;19(1):769-. doi: 10.1186/s12879-019-4371-y.
563 PubMed PMID: 31481123.
- 564 36. Oostenbrink R, Thompson M, Steyerberg EW. Barriers to translating diagnostic
565 research in febrile children to clinical practice: a systematic review. *Archives of disease in
566 childhood*. 2012;97(7):667-72. Epub 2012/01/06. doi: 10.1136/archdischild-2011-300667.
567 PubMed PMID: 22219168.
- 568 37. McDonald CR, Weckman A, Richard-Greenblatt M, Leligdowicz A, Kain KC.
569 Integrated fever management: disease severity markers to triage children with malaria and
570 non-malarial febrile illness. *Malaria Journal*. 2018;17(1):353. doi: 10.1186/s12936-018-2488-
571 x.
- 572 38. Royston P, Moons KGM, Altman DG, Vergouwe Y. Prognosis and prognostic
573 research: Developing a prognostic model. 2009;338:b604. doi: 10.1136/bmj.b604 %J BMJ.
- 574 39. Chandna A, Osborn J, Bassat Q, Bell D, Burza S, D'Acremont V, et al. Anticipating
575 the future: prognostic tools as a complementary strategy to improve care for patients with
576 febrile illnesses in resource-limited settings. *BMJ Glob Health*. 2021;6(7). Epub 2021/08/01.
577 doi: 10.1136/bmjgh-2021-006057. PubMed PMID: 34330761; PubMed Central PMCID:
578 PMCPMC8327814.
- 579 40. Keitel K, Samaka J, Masimba J, Temba H, Said Z, Kagoro F, et al. Safety and
580 Efficacy of C-reactive Protein-guided Antibiotic Use to Treat Acute Respiratory Infections in
581 Tanzanian Children: A Planned Subgroup Analysis of a Randomized Controlled
582 Noninferiority Trial Evaluating a Novel Electronic Clinical Decision Algorithm (ePOCT).
583 *Clinical Infectious Diseases*. 2019;69(11):1926-34. doi: 10.1093/cid/ciz080.
- 584 41. Tan R, Kagoro F, Levine GA, Masimba J, Samaka J, Sangu W, et al. Clinical
585 Outcome of Febrile Tanzanian Children with Severe Malnutrition Using Anthropometry in
586 Comparison to Clinical Signs. *American Journal of Tropical Medicine and Hygiene*.
587 2020;102(2):427-35. doi: 10.4269/ajtmh.19-0553. PubMed PMID: WOS:000512881500035.
- 588 42. Bayes T. LII. An essay towards solving a problem in the doctrine of chances. By the
589 late Rev. Mr. Bayes, FRS communicated by Mr. Price, in a letter to John Canton, AMFR S.
590 *Philosophical transactions of the Royal Society of London*. 1763;(53):370-418.
- 591 43. Meredith V, Sandra M, Eamon C, Geoff N, Jonathan S, Matthew S, et al. Experienced
592 physician descriptions of intuition in clinical reasoning: a typology. *Diagnosis*. 2019;6(3):259-
593 68. doi: <https://doi.org/10.1515/dx-2018-0069>.

- 594 44. Van den Bruel A, Thompson M, Buntinx F, Mant D. Clinicians' gut feeling about
595 serious infections in children: observational study. *BMJ : British Medical Journal*.
596 2012;345:e6144. doi: 10.1136/bmj.e6144.
- 597 45. Dale AP, Marchello C, Ebell MH. Clinical gestalt to diagnose pneumonia, sinusitis,
598 and pharyngitis: a meta-analysis. *British Journal of General Practice*. 2019;69(684):e444.
599 doi: 10.3399/bjgp19X704297.
- 600 46. Greenhalgh T, Howick J, Maskrey N. Evidence based medicine: a movement in
601 crisis? *BMJ : British Medical Journal*. 2014;348:g3725. doi: 10.1136/bmj.g3725.
- 602 47. Harris M, Clark J, Cote N, Fletcher P, Harnden A, McKean M, et al. British Thoracic
603 Society guidelines for the management of community acquired pneumonia in children:
604 update 2011. *Thorax*. 2011;66 Suppl 2:ii1-23. Epub 2011/10/19. doi: 10.1136/thoraxjnl-2011-
605 200598. PubMed PMID: 21903691.
- 606 48. Bleeker SE, Derksen-Lubsen G, Grobbee DE, Donders AR, Moons KG, Moll HA.
607 Validating and updating a prediction rule for serious bacterial infection in patients with fever
608 without source. *Acta Paediatr*. 2007;96(1):100-4. Epub 2006/12/26. doi: 10.1111/j.1651-
609 2227.2006.00033.x. PubMed PMID: 17187613.
- 610 49. Mehl G, Tunçalp Ö, Ratanaprayul N, Tamrat T, Barreix M, Lowrance D, et al. WHO
611 SMART guidelines: optimising country-level use of guideline recommendations in the digital
612 age. *The Lancet Digital Health*. 2021. doi: 10.1016/S2589-7500(21)00038-8.
- 613 50. Sutton RT, Pincock D, Baumgart DC, Sadowski DC, Fedorak RN, Kroeker KI. An
614 overview of clinical decision support systems: benefits, risks, and strategies for success. *NPJ
615 Digit Med*. 2020;3:17. Epub 2020/02/13. doi: 10.1038/s41746-020-0221-y. PubMed PMID:
616 32047862; PubMed Central PMCID: PMC7005290.
- 617 51. Källander K, Tibenderana JK, Akpogheneta OJ, Strachan DL, Hill Z, ten Asbroek
618 AHA, et al. Mobile health (mHealth) approaches and lessons for increased performance and
619 retention of community health workers in low- and middle-income countries: a review.
620 *Journal of medical Internet research*. 2013;15(1):e17-e. doi: 10.2196/jmir.2130. PubMed
621 PMID: 23353680.
- 622 52. US Food and Drug Administration. Software as a Medical Device (SAMD). Clinical
623 Evaluation-Guidance for Industry and Food and Drug Administration Staff. 2017.
- 624 53. European Commission. Regulation (EU) 2017/745 of the European Parliament and of
625 the Council of 5 April 2017 on Medical Devices, Amending Directive 2001/83/EC, Regulation
626 (EC) No 178/2002 and Regulation (EC) No 1223/2009 and Repealing Council Directives
627 90/385/EEC and 93/42/EEC. *Official Journal of the European Union*. 2017;L 117/1.
- 628 54. Aranda-Jan CB, Mohutsiwa-Dibe N, Loukanova S. Systematic review on what works,
629 what does not work and why of implementation of mobile health (mHealth) projects in Africa.
630 *BMC public health*. 2014;14(1):188. doi: 10.1186/1471-2458-14-188.
- 631 55. Lampariello R, Ancellin-Panzani S. Mastering stakeholders' engagement to reach
632 national scale, sustainability and wide adoption of digital health initiatives: lessons learnt from
633 Burkina Faso. *Fam Med Community Health*. 2021;9(3). Epub 2021/06/20. doi: 10.1136/fmch-
634 2021-000959. PubMed PMID: 34144970; PubMed Central PMCID: PMC7005290.
- 635 56. Florez ID, Brouwers MC, Kerkvliet K, Spithoff K, Alonso-Coello P, Burgers J, et al.
636 Assessment of the quality of recommendations from 161 clinical practice guidelines using the
637 Appraisal of Guidelines for Research and Evaluation–Recommendations Excellence
638 (AGREE-REX) instrument shows there is room for improvement. *Implementation Science*.
639 2020;15(1):79. doi: 10.1186/s13012-020-01036-5.
- 640 57. Maaløe N, Ørtved AMR, Sørensen JB, Sequeira Dmello B, van den Akker T, Kujabi
641 ML, et al. The injustice of unfit clinical practice guidelines in low-resource realities. *The
642 Lancet Global Health*. 2021. doi: 10.1016/S2214-109X(21)00059-0.
- 643 58. Tamrat T, Ratanaprayul N, Barreix M, Tunçalp Ö, Lowrance D, Thompson J, et al.
644 Transitioning to Digital Systems: The Role of World Health Organization's Digital Adaptation
645 Kits in Operationalizing Recommendations and Interoperability Standards. *Global Health:
646 Science and Practice*. 2022. doi: 10.9745/GHSP-D-21-00320.
- 647 59. Qaseem A, Forland F, Macbeth F, Ollenschläger G, Phillips S, van der Wees P.
648 Guidelines International Network: toward international standards for clinical practice

- 649 guidelines. *Annals of internal medicine*. 2012;156(7):525-31. Epub 2012/04/05. doi:
650 10.7326/0003-4819-156-7-201204030-00009. PubMed PMID: 22473437.
- 651 60. Cornick R, Picken S, Wattrus C, Awotiwon A, Carkeek E, Hannington J, et al. The
652 Practical Approach to Care Kit (PACK) guide: developing a clinical decision support tool to
653 simplify, standardise and strengthen primary healthcare delivery. *BMJ Global Health*.
654 2018;3(Suppl 5):e000962. doi: 10.1136/bmjgh-2018-000962.
- 655 61. Loftus TJ, Tighe PJ, Ozrazgat-Baslanti T, Davis JP, Ruppert MM, Ren Y, et al. Ideal
656 algorithms in healthcare: Explainable, dynamic, precise, autonomous, fair, and reproducible.
657 *PLOS Digital Health*. 2022;1(1):e0000006. doi: 10.1371/journal.pdig.0000006.
- 658 62. Watts G. The Tanzanian digital health agenda. *The Lancet Digital Health*.
659 2020;2(2):e62-e3. doi: 10.1016/S2589-7500(20)30005-4.
- 660 63. Lange S, Mwisongo A, Mæstad O. Why don't clinicians adhere more consistently to
661 guidelines for the Integrated Management of Childhood Illness (IMCI)? *Soc Sci Med*.
662 2014;104:56-63. Epub 2014/03/04. doi: 10.1016/j.socscimed.2013.12.020. PubMed PMID:
663 24581062.
- 664 64. World Health Organization. Ethics and governance of artificial intelligence for health:
665 WHO guidance. 2021.
- 666 65. Kundu S. AI in medicine must be explainable. *Nature Medicine*. 2021;27(8):1328-.
- 667 66. Amann J, Vetter D, Blomberg SN, Christensen HC, Coffee M, Gerke S, et al. To
668 explain or not to explain?—Artificial intelligence explainability in clinical decision support
669 systems. *PLOS Digital Health*. 2022;1(2):e0000016. doi: 10.1371/journal.pdig.0000016.
- 670
- 671

672 **Author contributions:**

673 Conceptualization of manuscript: RT, VDA, KK; Development of ePOCT+ clinical algorithms: RT, GL,
674 NV, FB, LCo, OdS, LL, CM, NS, KM, HN, LCh, VR, TD, JN, ER, LT, LM, MB, RM, AM, PA, ON, MF,
675 AT, SA, KS, GK, VDA, KK; Development of medAL-creator and medAL-reader software: VF, AV, RT,
676 OdS, FB, LCo, GL, AK, KK, VDA, JT; Delphi survey: JVDM, LL, RT, KK; Statistical analyses: RT, AH;
677 Drafted the first draft: RT; Commented and edited the first draft: KK, VDA; Commented on, edited and
678 approved the final draft: all

679 **Supporting information captions**

680 **S1 Appendix: Prevalence of specific symptoms and diagnoses not covered in IMCI from**

681 **Tanzania**

682 **S2 Appendix: Delphi survey on the reliability and feasibility of measurement of symptoms and**

683 **signs**

684 **S3 Appendix: Prognostic value of predictors used in the ePOCT and ALMANACH electronic**

685 **clinical decision support algorithms**

686 **S4 Appendix: Features of the medAL-creator and medAL-reader software as defined by a**

687 ***clinical-IT collaboration with end-user feedback***

688

689 **S5 Appendix: Evaluation of ePOCT+ based on the characteristics set by the target product**

690 **profile for electronic clinical decision support algorithm as defined by expert consensus**

691

692

693